22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
00:17 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Shire's intrathecal ERT misses in MPS II trial

Shire plc (LSE:SHP; NASDAQ:SHPG) reported top-line data showing that intrathecal idursulfase (SHP609; formerly HGT-2310) missed the primary endpoint in the Phase II/III HGT-HIT-094 trial to treat pediatric patients with mucopolysaccharidosis II (MPS II, Hunter syndrome)...
22:59 , Dec 19, 2017 |  BC Extra  |  Clinical News

Shire's intrathecal ERT misses in MPS II trial

Shire plc (LSE:SHP; NASDAQ:SHPG) said intrathecal idursulfase (SHP609; formerly HGT-2310) missed the primary endpoint in the Phase II/III HGT-HIT-094 trial to treat pediatric patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) and cognitive impairment. The...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

AGT-182: Phase I/IIa data

Data from the first cohort of 4 Hunter syndrome patients ages >=18 in the open-label, international Phase I/IIa Breaking Barriers trial showed that once-weekly 1 mg/kg IV AGT-182 for 8 weeks was generally well tolerated....
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

ArmaGen, Shire deal

ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment from Shire under a 2014 deal granting Shire rights to AGT-182 . The milestone was triggered by the start of patient dosing in a...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

AGT-182: Phase I started

ArmaGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1 and 3 mg/kg IV AGT-182 once weekly for 8 weeks in about 12 patients. The trial start triggered an undisclosed milestone payment to...
07:00 , Mar 12, 2015 |  BC Innovations  |  Product R&D

Extending zinc fingers

After test-driving its gene editing technology in hemophilia through a partnership with Shire plc , Sangamo BioSciences Inc. is expanding its zinc finger nuclease platform to two new indications, Hurler syndrome and Hunter syndrome. This...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Shire, ArmaGen deal

ArmaGen granted Shire exclusive, worldwide rights to develop and commercialize AGT-182 , which is in development to treat mucopolysaccharidosis type II (MPS-II, Hunter’s syndrome). ArmaGen will receive $15 million up front in cash and equity....
00:58 , Jul 24, 2014 |  BC Extra  |  Company News

ArmaGen licenses AGT-182 to Shire

ArmaGen Technologies Inc. (Calabasas, Calif.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to develop and commercialize AGT-182 , which is in development to treat mucopolysaccharidosis type II (MPS-II, Hunter's syndrome). ArmaGen will receive $15...